This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zeltherva

SELLAS Life Sciences Group

Drug Names(s): SLS001, SLS-001, WT1 Cancer Vaccine, WT-1 Vaccine

Description: The WT-1 vaccine was assembled from a set of immunogenic peptides that are capable of stimulating both CD4 and CD8 T cells.

Deal Structure: Sellas and MSK
In September 2014, SELLAS Life Sciences Group announced that it has signed an exclusive global collaboration and license agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development, marketing, and commercialization of MSKs proprietary WT1 cancer vaccine. Financial details were not disclosed.


Zeltherva News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug